Cargando…

Vulvar carcinoma: dilemma, debates, and decisions

Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Swarupa, Sharma, Manoj Kumar, Kaur, Inderjeet, Khurana, Ruparna, Modi, Kanika Batra, Narang, Raman, Mandal, Avik, Dutta, Soumya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765975/
https://www.ncbi.nlm.nih.gov/pubmed/29386916
http://dx.doi.org/10.2147/CMAR.S143316
_version_ 1783292302953807872
author Mitra, Swarupa
Sharma, Manoj Kumar
Kaur, Inderjeet
Khurana, Ruparna
Modi, Kanika Batra
Narang, Raman
Mandal, Avik
Dutta, Soumya
author_facet Mitra, Swarupa
Sharma, Manoj Kumar
Kaur, Inderjeet
Khurana, Ruparna
Modi, Kanika Batra
Narang, Raman
Mandal, Avik
Dutta, Soumya
author_sort Mitra, Swarupa
collection PubMed
description Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes. Surgery appears to be the only curative treatment option in the early stages of the disease. But in most patients, surgery is associated with considerable morbidities and psychosexual issues. Hence, in the quest for a less morbid form of treatment, multimodality approaches with various combinations of surgery, chemotherapy, and radiation therapy have been suggested for advanced vulvar cancers. Due to the low incidence of the disease, the level of evidence for the success of these treatment modalities is poor. In countries like India, a heterogeneous incidence of vulvar carcinoma exists across the country, with patients presenting at advanced stages when the option of surgery is often supplemented or replaced by chemotherapy and radiotherapy. In this review, we attempt to study the available published literature and trials and discuss the treatment options in various stages of vulvar carcinoma.
format Online
Article
Text
id pubmed-5765975
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57659752018-01-31 Vulvar carcinoma: dilemma, debates, and decisions Mitra, Swarupa Sharma, Manoj Kumar Kaur, Inderjeet Khurana, Ruparna Modi, Kanika Batra Narang, Raman Mandal, Avik Dutta, Soumya Cancer Manag Res Review Vulvar carcinoma is a rare and aggressive gynecological malignancy. It affects elderly females, with the mean age at diagnosis being 55–60 years. Regional metastasis to inguinal lymph nodes is common. There is a high incidence of pelvic node involvement, especially in those with pathologically positive inguinal nodes. Surgery appears to be the only curative treatment option in the early stages of the disease. But in most patients, surgery is associated with considerable morbidities and psychosexual issues. Hence, in the quest for a less morbid form of treatment, multimodality approaches with various combinations of surgery, chemotherapy, and radiation therapy have been suggested for advanced vulvar cancers. Due to the low incidence of the disease, the level of evidence for the success of these treatment modalities is poor. In countries like India, a heterogeneous incidence of vulvar carcinoma exists across the country, with patients presenting at advanced stages when the option of surgery is often supplemented or replaced by chemotherapy and radiotherapy. In this review, we attempt to study the available published literature and trials and discuss the treatment options in various stages of vulvar carcinoma. Dove Medical Press 2018-01-09 /pmc/articles/PMC5765975/ /pubmed/29386916 http://dx.doi.org/10.2147/CMAR.S143316 Text en © 2018 Mitra et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Mitra, Swarupa
Sharma, Manoj Kumar
Kaur, Inderjeet
Khurana, Ruparna
Modi, Kanika Batra
Narang, Raman
Mandal, Avik
Dutta, Soumya
Vulvar carcinoma: dilemma, debates, and decisions
title Vulvar carcinoma: dilemma, debates, and decisions
title_full Vulvar carcinoma: dilemma, debates, and decisions
title_fullStr Vulvar carcinoma: dilemma, debates, and decisions
title_full_unstemmed Vulvar carcinoma: dilemma, debates, and decisions
title_short Vulvar carcinoma: dilemma, debates, and decisions
title_sort vulvar carcinoma: dilemma, debates, and decisions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765975/
https://www.ncbi.nlm.nih.gov/pubmed/29386916
http://dx.doi.org/10.2147/CMAR.S143316
work_keys_str_mv AT mitraswarupa vulvarcarcinomadilemmadebatesanddecisions
AT sharmamanojkumar vulvarcarcinomadilemmadebatesanddecisions
AT kaurinderjeet vulvarcarcinomadilemmadebatesanddecisions
AT khuranaruparna vulvarcarcinomadilemmadebatesanddecisions
AT modikanikabatra vulvarcarcinomadilemmadebatesanddecisions
AT narangraman vulvarcarcinomadilemmadebatesanddecisions
AT mandalavik vulvarcarcinomadilemmadebatesanddecisions
AT duttasoumya vulvarcarcinomadilemmadebatesanddecisions